Home use of the GlucoWatch G2 biographer in children with diabetes

Related Experiment Video

Updated: Aug 19, 2026

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

Eba Hathout1, Nina Patel, Christina Southern

  • 1Pediatric Diabetes Center, Loma Linda University, 11175 Campus St, CP A1120R, Loma Linda, CA 92354, USA. ehathout@ahs.llumc.edu.

Pediatrics
|March 3, 2005
PubMed

Insights

The GlucoWatch G2 Biographer (GW2B) is safe and usable for children with type 1 diabetes. This device effectively detects nocturnal hypoglycemia in younger children.

Area of Science:

  • Pediatric Endocrinology
  • Medical Device Technology
  • Diabetes Management

Background:

  • Continuous glucose monitoring is crucial for managing type 1 diabetes in children.
  • The GlucoWatch G2 Biographer (GW2B) is a wearable device designed for glucose monitoring.
  • Evaluating its performance in pediatric populations is essential.

Purpose of the Study:

  • To assess the usability, accuracy, and hypoglycemia detection capabilities of the GW2B in children aged 1 to 17 years.
  • To determine the safety and efficacy of the GW2B for extended wear in a home setting.
  • To specifically evaluate its ability to detect asymptomatic nocturnal hypoglycemia.

Main Methods:

  • A 3-month extended-wear study involving 46 children (aged 1-17) with type 1 diabetes.
  • Children underwent multiple 15-hour wear periods (day and night) weekly.
  • Paired GW2B and blood glucose meter readings were collected for accuracy assessment, alongside HbA1c and insulin dose monitoring.

Main Results:

  • Accuracy assessment showed correlation coefficients of 0.58 (<7 years) and 0.74 (≥7 years).
  • The GW2B detected 42 hypoglycemia episodes, with 33 confirmed by meter; sensitivity was ~79%, specificity ~83%.
  • No significant changes in HbA1c or insulin dose were observed; no significant side effects were reported.

Conclusions:

  • The GW2B demonstrates usability and safety in children of all tested ages in a home environment.
  • The device is capable of detecting asymptomatic nocturnal hypoglycemia, particularly in younger children.
  • The GW2B offers a potentially valuable tool for diabetes management in pediatric patients.
Abstract

Related Concept Videos

Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
Hyperglycemia01:29

Hyperglycemia

Hyperglycemia is an abnormally high blood glucose level. It is diagnosed by fasting glucose ≥126 mg/dL, 2-hour oral glucose tolerance test (or OGTT) ≥200 mg/dL, random glucose ≥200 mg/dL with symptoms, or HbA1c ≥6.5%. However, HbA1c results may be unreliable in certain conditions, such as anemia or hemoglobinopathies, and the diagnosis should be confirmed unless classic symptoms are present. Postprandial hyperglycemia is typically considered significant when glucose levels exceed 180 mg/dL two...
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Oral Hypoglycemic Agents: &#945;-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...